|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>17</b>, a potent dual VEGFR3 and VEGFR2 inhibitor, effectively suppresses both lymphangiogenesis and angiogenesis in a 3D-microfluidic tumor lymphangiogenesis assay and in vivo corneal assay while SAR131675 blocks only lymphangiogenesis.
|
31513411 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor growth in mice challenged 3 months after transplantation with tsFlk-1-expressing bone marrow cells was significantly inhibited when compared with tumor growth in control-transplanted mice.
|
11555605 |
2001 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor endothelial cell KIT expression was strongly (P < 0.01) associated with endothelial cell phospho-KIT and SCF expression, and with tumor KIT (P = 0.0011) and VEGFR-2 expression (P = 0.022).
|
20030644 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor vessel models were sensitive to VEGFR2-blocking antibody DC101, whereas the stromal vessel models were exclusively refractory.
|
24030704 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumors treated simultaneously with apatinib and cisplatin exhibited significantly-increased inhibition of tumor growth, prolonged survival time, decreased expression of VEGFR-2, reduced microvascular density, and frequency of apoptosis over standalone and sequential administration therapy.
|
28881773 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
KDR was also highly induced in nonfunctioning tumors (14-fold, P < 0.001, n = 78) as well as in the whole cohort of pituitary tumors, compared with normal pituitary samples (14-fold, P < 0.0001, n = 100).
|
12213878 |
2002 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
KDR promoter-HSV-tk gene may effectually restrain the growth of tumor via targeting angiogenesis for hepatocellular carcinoma with treatment of GCV.
|
17663519 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
VEGFR-2 increase was also observed in vivo in a mouse model of xenograph tumors overexpressing EMMPRIN.
|
19837976 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
KDR mRNA and protein expression and microvessel density (MVD) were measured in non-small cell lung cancer (NSCLC) tumor samples, and matching patient DNA samples were genotyped to test for associations with variants of interest.
|
21712447 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
KDR copy number gains (CNG), measured by quantitative PCR and fluorescence in situ hybridization, were detected in 32% of tumors and associated with significantly higher KDR protein and higher microvessel density than tumors without CNGs.
|
21724587 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Flk-1 shRNA restrained VM in tumors and subsequently inhibited tumor development.
|
22654102 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
VEGFR-2 recombinant adenovirus modified with oxidized mannan was constructed as a tumor vaccine to immunize mice in vivo.
|
24525706 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
VEGFR2 and VEGFR3 receptor expression were also studied by qRT-PCR in 17 tumors in comparison to normal endometrium.
|
24845798 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
VEGFR blockade inhibits the process of tumor vasculogenesis occurring during tumor hypoxia whereas the effect of VEGF inhibition appears restricted to differentiated endothelial cells.
|
25948774 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium.
|
30810838 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
KDR and flt1 mRNA were limited to tumor endothelial cells and were more strongly expressed in the hepatic metastases than in the sinusoidal endothelium of the surrounding liver parenchyma.
|
7535799 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A tumor was considered FISH positive for KIT and/or VEGFR2 if it displayed copy number gain and/or amplification.
|
22170730 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A VEGFR inhibitor which preferentially suppressed tumor growth in NK cell-depleted mice was dependent on neutrophils.
|
29362222 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A cyclic peptide reproducing the α1 helix of VEGF-B binds to VEGFR-1 and VEGFR-2 and inhibits angiogenesis and tumor growth.
|
30700502 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A multivariate model identified ECOG performance status, and tumour morphometry, along with cyclin D1, caspase-3 activated, and phosphorylated KDR to be associated with overall survival, concordance index of 0.74 (hazard ratio (HR) 5.26, p-value 0.0002).
|
19272767 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A new enhanced Semliki Forest virus (SFV) expression vector is now available and this is particularly effective when used in combination with pro-inflammatory cytokines such as IL-12 or anti-angiogenic treatment based on the induction of autoimmunity to tumor endothelial cell antigen (vascular endothelial growth factor receptor 2).
|
18221060 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Accordingly, green fluorescent protein-positive neovessels infiltrate the graft when tumor cells are injected in transgenic VEGFR2:G-RCFP zebrafish embryos that express green fluorescent protein under the control of the VEGFR2/KDR promoter.
|
17409396 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, interfering with the methylation of VEGFR-2 by pharmacological inhibition or by site-directed mutagenesis revealed that methylation of Lys(1041) was required for VEGFR-2-mediated angiogenesis in zebrafish and tumor growth in mice.
|
24300896 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Additionally, the immuno-fluorescent staining results confirmed the expression pattern of VEGFR-2 among various PrCa tumors.
|
31598404 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, these tumors show a significant reduction in growth, a response that is further heightened when therapeutic inhibition of VEGF receptor 2 (VEGFR2) is utilized in combination with hornerin knockdown.
|
28916756 |
2017 |